MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Results From a Dose-Blinded, Phase II Extension Study Evaluating Long-Term Efficacy, Safety and Tolerability of Minzasolmin in Participants With Parkinson’s Disease

    C. Beuter, S. Carson, M. Key Prato, N. Massat, R. Maguire, A. Dhar Koul, E. Lucassen, J-M. Riethusien, I. Giunzioni, A. Pethe, G. Goethals, A. Khanna, Z. Ali (Monheim am Rhein, Germany)

    Objective: ORCHESTRA XT (PD0055; NCT05543252) was a Phase II, dose-blinded extension of the ORCHESTRA Phase II, proof-of-concept study (NCT04658186). ORCHESTRA XT assessed the pharmacodynamic effects of…
  • 2025 International Congress

    Efficacy of Combined Transcranial Direct Current Stimulation (tDCS) and Gait Training on Gait in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    A. Hegazi, H. Hussein, R. Mohamed (Mansoura, Egypt)

    Objective: To evaluate the effects of addition of tDCS to gait training  on gait parameters and motor function in individuals with Parkinson’s disease Background: Gait…
  • 2025 International Congress

    Effect of Exenatide on disease progression in early Parkinson’s disease–a randomized, placebo controlled, single-center trial in Sweden

    I. Markaki, CC. Tang, PE. Papathoma, L. Hainke, W. Paslawski, J. Paslawska, I. Savitcheva, U. Estenberg, D. Eidelberg, P. Svenningsson (Solna, Sweden)

    Objective: To identify biological mechanisms that mediate Exenatide's effect in the brain of patients with early Parkinson’s disease(PD). Background: Tracking PD progression remains a major challenge due to…
  • 2025 International Congress

    Addressing Sex and Gender Gaps in Parkinson’s Research: A Multi-Stakeholder Approach

    L. Smith, S. Hussain-Ali, R. Flanagan, C. Carroll, M. Auffret (London, United Kingdom)

    Objective: To describe and address sex and gender gaps in Parkinson’s disease (PD) research through a multidisciplinary, multi-stakeholder approach that includes patient representatives, researchers, clinicians,…
  • 2025 International Congress

    Increasing Physical Activity in Parkinson’s Disease Via a Remotely Deployed Gamification Intervention

    J. Morley, K. Waddell, M. Smith, S. Wood, R. Greysen (Philadelphia, USA)

    Objective: To determine feasibility and estimate effect of a remote behavioral intervention on daily steps and motor symptoms in Veterans with PD Background: Many types…
  • 2025 International Congress

    Identifying subjects at high risk for prodromal Parkinson’s Disease using dopamine transporter imaging deficit in a step-wise recruitment strategy: Data of Healthy Brain Ageing (HeBA)

    S. Schade, C. Corinne, S. Ghosh, A. Garrido, E. Lang, P. Mahlknecht, C. Pauly, D. Pilco, R. Rautenkranz, K. Rege, S. Scaglione, S. Schnell, T. Wicke, V. Satagopam, M. Marti, E. Tolosa, W. Poewe, R. Krüger, C. Trenkwalder, B. Mollenhauer (Kassel, Germany)

    Objective: To optimize screening for subjects with dopamine transporter (DaT) imaging deficit being at high risk for prodromal Parkinson's disease (PD). Background: Efficient screening methods…
  • 2025 International Congress

    Longitudinal Remote Monitoring with Wearable Technology in Parkinson Disease: Initiation of A Dyskinesia Insight Network Observational Study

    R. Gilron, A. Hare, M. Grall, P. Qin, S. Isaacson (San Francsico, USA)

    Objective: Evaluate the utility of wearable digital health technology for identifying and characterizing levodopa-induced dyskinesia in real-world settings. Background: Patients with Parkinson disease (PwP) frequently…
  • 2025 International Congress

    Retro walking: A Potential Indicator of Physical Frailty in Parkinson’s Disease.

    M. van Emde-Boas, C. Stonsaovapak, N. Bohnen, C. Pongmala (Ann Arbor, USA)

    Objective: To examine the associations between retro walking and frailty parameters such as low grip strength, exhaustion, low physical activity and weight loss and compare…
  • 2025 International Congress

    A Proof-of-Concept Study of TR-012001, a Nasal Levodopa, in Patients With Parkinson’s Disease With OFF Episodes, Without Dopa Decarboxylase Inhibitor

    M. Nomoto, H. Yabe, R. Ando, Y. Sumiyoshi, T. Akagi, R. Ise, Y. Akiyoshi, C. Date, S. Nakano, R. Suzuki, Y. Sonoda, S. Haruta, S. Kanazashi, A. Mori, I. Nagata (Tokyo, Japan)

    Objective: To evaluate the safety, tolerability, levodopa pharmacokinetics, and exploratory efficacy of TR-012001 in Parkinson’s disease (PD). Background: TR-012001 is a novel investigational prefilled nasal…
  • 2025 International Congress

    Reduced Falls With ND0612: Supportive Analyses From the BouNDless Phase 3 Study

    S. Isaacson, F. Stocchi, A. Ellenbogen, N. Lopes, N. Sasson, J. Pereira, O. Rascol (Boca Raton, USA)

    Objective: Explore potential reasons for the lower rates of falls with ND0612 vs immediate-release levodopa/carbidopa (IR-LD/CD) therapy reported in the BouNDless study. Background: Falls are…
  • « Previous Page
  • 1
  • …
  • 142
  • 143
  • 144
  • 145
  • 146
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley